

Table 1

Treatment	Time intervall after cell injection [min]			
	0 - 10	11 - 20	21 - 30	31 - 40
adherent cells / 20 microscopic fields [mean \pm SD]				
T 84				
control IgG [n=6]	16.7 \pm 9.0	15.8 \pm 5.1	14.1 \pm 5.6	13.0 \pm 1.9
HT-29 LMM				
control IgG [n=9]	13.5 \pm 5.1	13.5 \pm 4.8	11.1 \pm 2.7	13.5 \pm 2.3
anti integrin- β 1 [n=7]	11.4 \pm 4.7	11.8 \pm 4.4	12.9 \pm 2.7	12.3 \pm 3.8
anti integrin- β 4 [n=10]	13.4 \pm 7.6	10.7 \pm 4.0	10.4 \pm 3.2	11.0 \pm 4.5
anti integrin- α v [n=8]	10.6 \pm 5.1	10.1 \pm 4.1	9.5 \pm 2.5	11.7 \pm 2.7
vehicle [n=12]	12.8 \pm 4.7	13.2 \pm 6.7	10.9 \pm 3.9	15.0 \pm 5.9
neuraminidase type V [n=8]	7.4 \pm 3.0	6.6 \pm 2.3*	6.5 \pm 2.6*	7.9 \pm 2.9**
fucoidane (animals) [n=7]	11.6 \pm 6.9	7.4 \pm 3.1*	7.2 \pm 3.3*	5.6 \pm 2.5**
control medium [n=5]	10.9 \pm 5.1	18.3 \pm 10.1	16.4 \pm 3.9	14.8 \pm 6.1
anti galectin-3 [n=5]	18.8 \pm 6.7	13.3 \pm 2.4	13.1 \pm 2.9	12.3 \pm 3.2
anti TF [n=4]	11.5 \pm 14.7	7.9 \pm 4.7*	8.6 \pm 3.7**	7.2 \pm 4.0*
anti TF + anti galectin-3 [n=5]	11.6 \pm 1.0	7.4 \pm 2.8**	7.3 \pm 2.3**	6.5 \pm 1.4**

ANOVA and post hoc (LSD):

* p<0.05

** p<0.001